Germline mutations in BRCA1 (MIM # 113705) and BRCA2 (MIM # 600185) are estimated to account for about 80% of breast/ovarian cancer families and 20% to 50% of site-specific breast cancer families [1-3]. Here, BRCA2 is linked to ovarian carcinoma.